Natac Natural Ingredients S.A.

NAT.MC has a liquidity risk profile that is characterized by a current ratio of 0.58, indicating that the company's current liabilities exceed its current assets, which could pose challenges in meeting short-term obligations. The company's liquidity position is further complicated by a negative net cash position after subtracting total debt, suggesting that the company may need to rely on external financing or asset sales to fund operations.

In terms of profitability, NAT.MC's return on equity (ROE) is 2.38%, which is relatively low, and its return on assets (ROA) is 0.76%, indicating that the company is not generating substantial returns on its asset base. These figures are below the typical thresholds for the pharmaceutical industry, suggesting that the company may be underperforming compared to its peers in terms of capital efficiency and profitability.

The company's revenue is primarily concentrated in a single segment, with no disclosed geographic diversification, which could expose it to regional economic downturns or regulatory changes. This lack of diversification may increase the company's vulnerability to market-specific risks, such as changes in healthcare policies or reimbursement rates in its primary market.

Looking at the growth trajectory, NAT.MC's capital expenditure of -11.6 million EUR indicates a reduction in investment in long-term assets, which could signal a strategic shift or financial constraints. The company's free cash flow is negative at -3.08 million EUR, suggesting that it is not generating enough cash from operations to cover its capital expenditures, which may limit its ability to invest in growth opportunities.

The risk assessment for NAT.MC highlights a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 1.51 indicates a relatively high level of leverage, which could increase financial risk, especially in a volatile market. The low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, which is a positive sign for existing shareholders.

Recent events and filings do not provide specific details on new product launches or strategic partnerships, but the company's financial performance and capital structure suggest a need for careful monitoring of its liquidity and debt management strategies. The company's operating cash flow of 3.79 million EUR is a positive indicator, but it must be managed effectively to address the negative free cash flow and capital expenditure needs.